Literature DB >> 2070332

Prognostic factors in papillary carcinoma of the thyroid.

A M Schindler1, G van Melle, B Evequoz, B Scazziga.   

Abstract

In a retrospective study of 119 patients, followed for 1 to 30 years after treatment of a papillary carcinoma of the thyroid, the authors searched for possible prognostic factors of the risk of recurrence. Microcarcinomas, anaplastic tumors and Hürthle cell carcinomas were excluded from the study. In a univariate analysis, age (greater than 45 years), sex (male), loss of histologic differentiation, size (greater than 3 cm), presence of carcinomatous lymphangitis, extrathyroid extension, and presence of metastasis at diagnosis were associated with a higher recurrence rate; type of growth and multifocality were not significant. In a multivariate analysis (logistic regression), age, size, and carcinomatous lymphangitis were significant predictors for women, whereas metastasis at diagnosis and cystic growth were significant for men.

Entities:  

Mesh:

Year:  1991        PMID: 2070332     DOI: 10.1002/1097-0142(19910715)68:2<324::aid-cncr2820680220>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45 years.

Authors:  Yasuhiro Ito; Chisato Tomoda; Takashi Uruno; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

2.  Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival.

Authors:  Yasuhiro Ito; Chisato Tomoda; Takashi Uruno; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

3.  A Case of Multifocal Papillary Thyroid Carcinoma Consisting of One Encapsulated Follicular Variant with BRAF K601E Mutation and Three Conventional Types with BRAF V600E Mutation.

Authors:  Wook Youn Kim; Young Sin Ko; Tae Sook Hwang; Hye Seung Han; So Dug Lim; Wan Seop Kim; Seo Young Oh
Journal:  Korean J Pathol       Date:  2013-06-25

Review 4.  TNM classification of thyroid carcinoma.

Authors:  Ashok R Shaha
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

5.  Needle tract implantation of papillary thyroid carcinoma after fine-needle aspiration biopsy.

Authors:  Yasuhiro Ito; Chisato Tomoda; Takashi Uruno; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2005-12       Impact factor: 3.352

6.  Optimizing the treatment of AMES high-risk papillary thyroid carcinoma.

Authors:  Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

7.  Prognostic impact of extrathyroid extension and clinical lymph node metastasis in papillary thyroid carcinoma depend on carcinoma size.

Authors:  Mitsuhiro Fukushima; Yasuhiro Ito; Mitsuyoshi Hirokawa; Akihiro Miya; Kazuo Shimizu; Akira Miyauchi
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

8.  Multivariate analysis of risk factors influencing survival in 110 ethnic Chinese with papillary thyroid cancer.

Authors:  T G Lorentz; P W Lau; C Y Lo; W L Law; K Y Wan; I J Lauder
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

Review 9.  Multifocal papillary thyroid carcinoma--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Maurizio Iacobone; Svante Jansson; Marcin Barczyński; Peter Goretzki
Journal:  Langenbecks Arch Surg       Date:  2013-11-22       Impact factor: 3.445

10.  Incidental papillary microcarcinoma of the thyroid--factors affecting lymph node metastasis.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Orhan Celen; Hüsnü H Mersin
Journal:  Langenbecks Arch Surg       Date:  2007-08-10       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.